Hans Lee, MD, and Natasha Edwin, MD, discuss how they prioritize making bispecific antibodies available in the community setting for multiple myeloma.
Natasha Edwin, MD
Advertisement
Natasha Edwin, MD, is a hematologist and medical oncologist at Providence Cancer Center Oncology and Hematology Care Clinic in Portland, OR.
Articles by Natasha Edwin, MD
Has CAR T Access Improved 1 Year After REMS Elimination?
Published: | Updated:
Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Learn how community oncologists deliver bispecific antibodies safely: step-up dosing, CRS prevention, infection support, and patient counseling.
Advertisement
Latest Updated Articles
Has CAR T Access Improved 1 Year After REMS Elimination?Published: October 19th 2026 | Updated: October 23rd 2026
Edwin on Bringing Bispecifics Closer to HomeAugust 14th 2026
- Has CAR T Access Improved 1 Year After REMS Elimination?
Published: October 19th 2026 | Updated: October 23rd 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5